poisar

Stocks · News reference

Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target

Aug 27, 2026, 1:21 PMBenzinga Newsdesk

Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CBIO
Source
benzinga
Observed
Aug 27, 2026, 1:21 PM
Checked
Aug 27, 2026, 1:21 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Jul 30, 2026, 11:35 AMNot Specified

    Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

    Crescent Biopharma reported Q2 2026 results with continued enrollment in its ASCEND Phase 1/2 trial for CR-001, a PD-1 x VEGF bispecific antibody. The company completed a $143.7 million public offering extending cash runway to H2 2028 and announced multiple clinical data readouts expected beginning Q1 2027. R&D expenses increased to $19.4 million due to expanded clinical activities, while the company maintains strategic partnerships with Kelun-Biotech for development in Greater China.

    Read original at globenewswire-inc
    CBIO